In a patient on valproic acid (Depakote) 125 mg twice daily and lactulose who is symptomatic, what does an ammonia level of 58 µmol/L indicate and how should it be managed?

Understanding Ammonia Levels in Valproic Acid-Induced Hyperammonemia

Your patient's ammonia level of 58 µmol/L is elevated and clinically significant despite being below the lab's upper reference limit of 120 µmol/L, and you should discontinue Depakote immediately given her symptoms. 1

The Critical Disconnect: Lab Reference Ranges vs. Clinical Reality

Your confusion is completely understandable—the lab reference range is misleading you. Here's what you need to know:

Normal ammonia levels are actually ≤35 µmol/L, not 120 µmol/L as your lab suggests 2. The pediatric guideline defines hyperammonemia as ≥50 µmol/L in term infants, children, and adolescents 2. Your patient's level of 58 µmol/L represents true hyperammonemia, not a lab error.

Why the Lab Range is Wrong for This Context

• Laboratory reference ranges often reflect the upper limits seen in general populations, not the threshold for clinical toxicity
• Valproic acid-induced hyperammonemia commonly occurs within "therapeutic" VPA ranges and at ammonia levels well below 120 µmol/L 3, 4
• Symptomatic hyperammonemia can develop at levels as low as 50-60 µmol/L, particularly in patients on valproate 3, 5

Immediate Management: Discontinue Depakote

The FDA label is explicit: "If ammonia is increased, valproate therapy should be discontinued" 1. This is not negotiable when the patient is symptomatic.

Why Discontinuation is Critical

• Valproate-induced hyperammonemia can progress to life-threatening encephalopathy
• Most symptomatic patients return to baseline mental status with normalized ammonia levels after VPA discontinuation 3, 6, 7
• Continuing valproate while treating hyperammonemia is fighting a losing battle—you're treating the consequence while maintaining the cause

The Lactulose Question: You're Using the Wrong Treatment

Lactulose is NOT the appropriate first-line treatment for valproic acid-induced hyperammonemia 5. This is a critical error in your current management.

Evidence Against Lactulose for VPA-Induced Hyperammonemia

• A 2025 study showed patients who initially received lactulose for VPA-induced hyperammonemia had slower recovery and longer hospital stays (98.9 hours vs. 90.3 hours) 5
• Lactulose is indicated for hepatic encephalopathy from liver cirrhosis 8, not drug-induced hyperammonemia
• Your patient doesn't have cirrhosis—she has drug toxicity

The Correct Treatment: L-Carnitine

L-carnitine (levocarnitine) is the appropriate pharmacologic treatment for symptomatic valproic acid-induced hyperammonemia 5, 7:

• Patients treated with levocarnitine alone had ammonia levels fall from 87 µmol/L to 64 µmol/L within 14 hours 5
• Recognition of VPA toxicity and prompt initiation of levocarnitine are associated with faster recovery and shorter hospital stays 5
• The FDA label recommends "appropriate interventions for treatment of hyperammonemia" after VPA discontinuation, which includes carnitine supplementation 1

Clinical Pitfalls to Avoid

Pitfall #1: Trusting the Lab Reference Range

The upper limit of 120 µmol/L is dangerously high for clinical decision-making. Levels >200 µmol/L are associated with poor neurological outcomes 2—you don't want to wait until your patient reaches that threshold.

Pitfall #2: Assuming Normal VPA Levels Mean Safety

Hyperammonemia occurs within therapeutic VPA ranges 3, 4. The prevalence of asymptomatic hyperammonemia ranges from 5-73%, and symptomatic cases from 0.7-22.2% 3. Your patient's low dose (125 mg twice daily) does NOT protect her—hyperammonemia has been reported with low doses and concentrations in older adults 4.

Pitfall #3: Attributing Symptoms to Other Causes

In patients on valproate who develop unexplained lethargy, vomiting, or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured 1. Your patient's symptoms are consistent with elevated ammonia, not something else.

Pitfall #4: Waiting for Liver Dysfunction

Hyperammonemia may be present despite normal liver function tests 1. The mechanism is not hepatotoxicity but rather valproate's interference with the urea cycle and carnitine metabolism 3.

Your Action Plan

1. Discontinue Depakote immediately 1
2. Stop lactulose—it's the wrong treatment and may delay recovery 5
3. Consider L-carnitine supplementation if symptoms persist or worsen 5, 7
4. Recheck ammonia levels in 12-24 hours to confirm downward trend
5. Switch to an alternative antiepileptic or mood stabilizer depending on her indication for Depakote
6. Consider screening for underlying urea cycle disorders if ammonia doesn't normalize quickly 1

The Bottom Line

Your patient has valproic acid-induced hyperammonemia at an ammonia level of 58 µmol/L. The lab's reference range of up to 120 µmol/L is clinically irrelevant—normal is ≤35 µmol/L. Discontinue Depakote, stop lactulose (which is for cirrhotic hepatic encephalopathy, not drug toxicity), and consider L-carnitine if needed. Most patients recover completely with VPA discontinuation alone.